Baseline characteristics of participants who had anti-SARS-CoV-2 spike antibodies measured 3–10 weeks following primary vaccination against SARS-CoV-2
| Variable | Infliximab | Vedolizumab | Overall | P value | |
| Vaccine | BNT162b2 | 44.7% (387/865) | 47.2% (202/428) | 45.6% (589/1293) | 0.41 |
| ChAdOx1 nCoV-19 | 55.3% (478/865) | 52.8% (226/428) | 54.4% (704/1293) | ||
| Age (years) | 41.4 (31.5–54.8) | 49.6 (37.1–63.8) | 43.8 (32.8–57.6) | <0.0001 | |
| Sex | Female | 50.3% (434/863) | 47.1% (200/425) | 49.2% (634/1288) | 0.19 |
| Male | 49.7% (429/863) | 52.7% (224/425) | 50.7% (653/1288) | ||
| Intersex | 0.0% (0/863) | 0.0% (0/425) | 0.0% (0/1288) | ||
| Prefer not to say | 0.0% (0/863) | 0.2% (1/425) | 0.1% (1/1288) | ||
| Ethnicity | White | 91.8% (791/862) | 89.9% (381/424) | 91.1% (1172/1286) | 0.62 |
| Asian | 5.3% (46/862) | 7.5% (32/424) | 6.1% (78/1286) | ||
| Mixed | 1.9% (16/862) | 1.9% (8/424) | 1.9% (24/1286) | ||
| Black | 0.7% (6/862) | 0.5% (2/424) | 0.6% (8/1286) | ||
| Other | 0.3% (3/862) | 0.2% (1/424) | 0.3% (4/1286) | ||
| Diagnosis | Crohn’s disease | 65.4% (566/865) | 40.7% (174/428) | 57.2% (740/1293) | 0.00050 |
| Ulcerative colitis or IBD unclassified | 34.6% (299/865) | 59.3% (254/428) | 42.8% (553/1293) | ||
| Duration of IBD (years) | 8.0 (4.0–16.0) | 10.0 (5.0–17.8) | 9.0 (4.0–16.0) | 0.0040 | |
| Age at IBD diagnosis (years) | 28.8 (21.6–41.8) | 34.0 (23.3–47.6) | 30.3 (21.9–43.7) | <0.0001 | |
| Immunomodulator | 61.6% (533/865) | 22.0% (94/427) | 48.5% (627/1292) | <0.0001 | |
| 5-ASA | 23.0% (199/865) | 31.6% (135/427) | 25.9% (334/1292) | 0.0012 | |
| Steroids | 3.0% (26/865) | 8.4% (36/427) | 4.8% (62/1292) | <0.0001 | |
| BMI (kg/m2) | 25.9 (22.8–30.6) | 26.1 (23.1–30.1) | 26.0 (22.9–30.4) | 0.75 | |
| Heart disease | 3.6% (31/865) | 6.5% (28/428) | 4.6% (59/1293) | 0.023 | |
| Diabetes | 3.8% (33/865) | 7.5% (32/428) | 5.0% (65/1293) | 0.0065 | |
| Lung disease | 13.5% (117/865) | 18.2% (78/428) | 15.1% (195/1293) | 0.032 | |
| Kidney disease | 1.2% (10/865) | 2.1% (9/428) | 1.5% (19/1293) | 0.22 | |
| Cancer | 0.5% (4/865) | 2.1% (9/428) | 1.0% (13/1293) | 0.013 | |
| Smoker | Yes | 9.7% (84/862) | 5.4% (23/425) | 8.3% (107/1287) | 0.0010 |
| Not currently | 32.0% (276/862) | 41.6% (177/425) | 35.2% (453/1287) | ||
| Never | 58.2% (502/862) | 52.9% (225/425) | 56.5% (727/1287) | ||
| Exposure to documented cases of COVID-19 | 9.4% (81/862) | 8.7% (37/425) | 9.2% (118/1287) | 0.76 | |
| Income deprivation score | 0.086 (0.052–0.151) | 0.084 (0.054–0.141) | 0.086 (0.052–0.147) | 0.94 | |
| Active disease (PRO2) | 4.9% (41/831) | 11.4% (46/405) | 7.0% (87/1236) | <0.0001 | |
Values presented are median (interquartile range) or percentage (numerator/denominator). P values represent the results of a Mann Whitney U, Kruskal Wallis or Fisher’s exact test.
5-ASA, 5-aminosalicylic acid; BMI, body mass index; IBD, inflammatory bowel disease; ; PRO2, IBD disease activity.